{"publisher":"Hydroquinone Rx","product":"Hydroquinone 8%","preparedAt":"2026-11-07","reviewStatus":"Research drafts; medical review has not been claimed","facts":[{"label":"Research finding 1","text":"A systematic review of published case studies of hydroquinone-associated ochronosis concluded that hydroquinone in concentrations above 4% and in treatment courses longer than 3 months may be associated with new-onset ochronosis.","href":"https://pubmed.ncbi.nlm.nih.gov/34486734/"},{"label":"Research finding 2","text":"A DailyMed listing from one labeler names a hydroquinone 8% / tretinoin 0.025% emulsion in a 30gm package, shows the marketing status unapproved drug other, and states that the drug has not been found by FDA to be safe and effective and that the labeling has not been approved by FDA.","href":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8953bbcf-2d3f-ee72-e053-2995a90a91d5"},{"label":"Research finding 3","text":"FDA states that currently Tri-Luma is the only FDA-approved drug containing hydroquinone, a prescription product approved for the short-term treatment of dark spots associated with moderate-to-severe melasma of the face.","href":"https://www.fda.gov/drugs/drug-safety-communications/fda-works-protect-consumers-potentially-harmful-otc-skin-lightening-products"},{"label":"Research finding 4","text":"FDA states that compounded drugs are not FDA-approved, which means FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.","href":"https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"},{"label":"Research finding 5","text":"A Cochrane review of melasma treatments concluded that the quality of studies evaluating melasma treatments was generally poor and available treatments inadequate, and called for high-quality randomised trials with long-term outcomes.","href":"https://pubmed.ncbi.nlm.nih.gov/20614435/"},{"label":"Research finding 6","text":"The Tri-Luma label (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) states that remission periods appeared to shorten between progressive courses of treatment and that few subjects (approximately 1 to 2%) maintained complete clearing of melasma.","href":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a35fa709-5eb5-4429-b38f-f1e0019bf0ee"},{"label":"Research finding 7","text":"The Tri-Luma label states that its safety and efficacy in patients of Fitzpatrick Skin Types V and VI have not been studied and that excessive bleaching in patients with darker skin cannot be excluded.","href":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a35fa709-5eb5-4429-b38f-f1e0019bf0ee"}],"sources":[{"title":"Tri-Luma (fluocinolone acetonide, hydroquinone, tretinoin) cream prescribing information","href":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a35fa709-5eb5-4429-b38f-f1e0019bf0ee"},{"title":"Drugs@FDA: NDA 021112 (fluocinolone acetonide, hydroquinone, tretinoin cream)","href":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021112"},{"title":"FDA: potentially harmful over-the-counter skin lightening products","href":"https://www.fda.gov/drugs/drug-safety-communications/fda-works-protect-consumers-potentially-harmful-otc-skin-lightening-products"},{"title":"FDA: compounding and FDA questions and answers","href":"https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"},{"title":"Cochrane review: interventions for melasma","href":"https://pubmed.ncbi.nlm.nih.gov/20614435/"}],"guides":[{"title":"Exogenous ochronosis: what the sources report","url":"https://hydroquinonerx.com/research-guides/exogenous-ochronosis-what-sources-report","description":"What labels, reviews, an observational study and an FDA page report about exogenous ochronosis, and what none of them measure.","date":"2026-11-10"},{"title":"FDA status of hydroquinone products and over-the-counter skin lighteners","url":"https://hydroquinonerx.com/research-guides/fda-status-of-hydroquinone-products-and-otc-skin-lighteners","description":"What the FDA states about the approved hydroquinone drug, OTC skin lighteners, mercury and DailyMed listings for unapproved hydroquinone products.","date":"2026-11-10"},{"title":"How long hydroquinone courses last and what happens after","url":"https://hydroquinonerx.com/research-guides/how-long-hydroquinone-courses-last-and-what-happens-after","description":"Time frames, maintenance and relapse as labels, studies and reviews state them, and that no source describes an on-off cycle for 8%.","date":"2026-11-10"},{"title":"Hydroquinone above 4%: what the sources say and do not say","url":"https://hydroquinonerx.com/research-guides/hydroquinone-above-4-percent-what-sources-say","description":"What the sources used here say, and do not say, about hydroquinone above 4%, ochronosis reports and unapproved listings.","date":"2026-11-10"},{"title":"Hydroquinone melasma trials: strengths, sizes and what they measured","url":"https://hydroquinonerx.com/research-guides/hydroquinone-melasma-trials-what-they-measured","description":"A plain summary of the melasma trials and reviews: the strengths, comparators, sizes, lengths and endpoints, and what they cannot show.","date":"2026-11-10"},{"title":"Hydroquinone, pregnancy and breastfeeding: what the sources state","url":"https://hydroquinonerx.com/research-guides/hydroquinone-pregnancy-and-breastfeeding","description":"What a Tri-Luma label, a hydroquinone 4% label, tretinoin sources and LactMed state about pregnancy and breastfeeding, reported as written.","date":"2026-11-10"},{"title":"Hydroquinone side effects, allergic reactions and when to call a provider","url":"https://hydroquinonerx.com/research-guides/hydroquinone-side-effects-allergic-reactions-and-when-to-call","description":"Irritation and allergy figures from labels and trials of hydroquinone creams, and what the sources say to do about a bad reaction.","date":"2026-11-10"},{"title":"Other pigment conditions, comparators and options: what the sources report","url":"https://hydroquinonerx.com/research-guides/other-pigment-conditions-comparators-and-options","description":"What small trials and reports say about hydroquinone outside melasma, against other agents and a laser, and what sources say about other options.","date":"2026-11-10"},{"title":"Sun protection and hydroquinone: what the sources say","url":"https://hydroquinonerx.com/research-guides/sun-protection-and-hydroquinone-what-sources-say","description":"What labels and a consensus abstract say about sunscreen and sun avoidance with hydroquinone, and where the evidence stops.","date":"2026-11-10"},{"title":"Tri-Luma label: what the approved triple-combination cream says","url":"https://hydroquinonerx.com/research-guides/tri-luma-label-what-the-approved-cream-says","description":"What the prescribing information for the approved fluocinolone acetonide, hydroquinone and tretinoin cream says about use, warnings and side effects.","date":"2026-11-10"},{"title":"What compounded hydroquinone means: what the FDA says about compounded drugs","url":"https://hydroquinonerx.com/research-guides/what-compounded-hydroquinone-means","description":"What the FDA says compounded drugs are and are not, the risks it names, section 503A, and two quality examples from other compounded products.","date":"2026-11-10"},{"title":"What hydroquinone is and how it might work","url":"https://hydroquinonerx.com/research-guides/what-hydroquinone-is-and-how-it-might-work","description":"How labels and reviews describe hydroquinone and melasma, and the different mechanisms proposed for hydroquinone, retinoids and niacinamide.","date":"2026-11-10"}]}